“Amyloidosis Treatment Market Report is set to have rapid growth due the Increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Amyloidosis Treatment Market Forecast 2019-2029: By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), By Country, And Segment Forecasts.

The global Amyloidosis Treatment market is poised for rapid growth between 2019 and 2029. The increase in the adoption of new targeted therapies and transplants, the emergence of biological drugs and the increase in the geriatric population are some of the factors that will collectively drive the market.

Amyloidosis is one of the rare diseases that are caused by the amyloid substance that starts to accumulate in different organs. Amyloid is a type of abnormal protein produced by bone marrow that can be stored in any organ or tissue. Diseases can affect different organs in different people; there are various types of illness. An estimated 16,000 people in the United States suffer from amyloidosis, with around 3,000 to 4,000 new cases reported each year.

The treatment of amyloidosis is growing due to factors such as; emerging organic sector, a growing number of elderly people around the world, a growing use of new ways (such as transplants and targeted therapies), etc. Therefore, the market for the treatment of amyloidosis is expected to expand and have an enormous range during the forecast period. Targeted therapies and stem cell transplants are catching on in developed countries. However, most of the world's population does not have access to sufficient health infrastructure to ensure rapid diagnosis and treatment in low-income economies.

Leading companies featured in the report include Pfizer, Inc.; Ionis Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd.; Johnson and Johnson Pvt. Ltd.; and Alnylam Pharmaceuticals, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever